Existing drugs may help more with breast cancer

More patients can benefit from highly effective breast cancer drugs that are already available, according to DNA sequencing studies by researchers at Washington University School of Medicine in St. Louis and other institutions. The investigators found that some women with the HER2 negative subtype may benefit from anti-HER2 drugs even though standard tests don’t indicate they are candidates for the drugs. Ron Bose, who treats patients at Washington University’s Siteman Cancer Center at Barnes-Jewish Hospital, is presenting the data at the San Antonio Breast Cancer Symposium. Read more here.